key: cord-0906793-l60ezjtb authors: Epstein, A.; Maiteki-Ssebuguzi, C.; Namuganga, J. F.; Nankabirwa, J. I.; Gonahasa, S.; Opigo, J.; Staedke, S. G.; Rutazaana, D.; Arinaitwe, E.; Kamya, M. R.; Bhatt, S.; Rodriguez-Barraquer, I.; Greenhouse, B.; Donnelly, M. J.; Dorsey, G. title: Resurgence of malaria in Uganda despite sustained indoor residual spraying and repeated long lasting insecticidal net distributions date: 2022-02-21 journal: nan DOI: 10.1101/2022.02.18.22271193 sha: bfd41d7217c267941fca487c4259eb0343382bad doc_id: 906793 cord_uid: l60ezjtb Five years of sustained indoor residual spraying (IRS) of insecticide from 2014 to 2019, first using a carbamate followed by an organophosphate, was associated with a marked reduction in the burden of malaria in five districts of Uganda. We assessed malaria burden over an additional 21 months, corresponding to a change in IRS formulations using clothianidin with and without deltamethrin and the start of the COVID-19 pandemic. We document an unprecedented resurgence in malaria burden: in years 4-5 of sustained IRS cases were 84% lower than the pre-IRS period, in year 6 this increased to a 43% reduction, and in the first 9 months of year 7, cases were 39% higher than pre-IRS levels. The timing of this resurgence corresponded to a change of active ingredient to clothianidin, a new IRS active ingredient. Further research is needed to determine mechanisms leading to this resurgence. Monthly adjusted IRRs and 95% confidence intervals (CI) for the 5 sites combined are presented 112 in Figure 2 and in Supplemental Table 1 . These results show there was an initial 52% reduction 113 in malaria burden in months 1 through 36 of sustained IRS (adjusted IRR = 0·48, 95% CI 0·36-114 0·64), followed by a continued improvement to an 84% reduction in burden in months 37 115 through 60 of sustained IRS (adjusted IRR = 0·16, 95% CI 0·12-0·22). In months 61 through 72, 116 however, malaria burden increased and was only 43% lower than the baseline period before IRS 117 was implemented (adjusted IRR = 0·57, 95% CI 0·44-0·74). During months 73 through 81 after 118 the initiation of IRS, there was a trend towards a higher malaria burden than the pre-IRS period 119 (adjusted IRR = 1·39, 95% CI 0·97-1·97). These results were consistent when including only 120 laboratory-confirmed cases unadjusted for testing rate as the model outcome (Supplemental 121 Figure 1 ) and when repeating the analysis leaving out the 2 sites that halted IRS campaigns after 122 2020 (Orum and Alebtong) (Supplemental Figure 2) . 123 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. ; https://doi.org/10.1101/2022.02.18.22271193 doi: medRxiv preprint Study Objective 2 129 Across the 15 sites over a 22 month period (January 2020 through October 2021) included in the 130 analysis for Objective 2, 583,344 outpatient visits were recorded (Table 2) . From January 2020 131 through December 2020, average monthly cases at IRS sites ranged from 64-594 and TPR 132 ranged from 10·9%-51·0%. From January 2021 through October 2021, these figures increased to 133 371-849 and 43·4%-60·1%, respectively. Average monthly cases increased in 4 of the 5 IRS sites 134 comparing January 2020 through December 2020 to January 2021 through October 2021, with 135 the exception of Dokolo (the first site to switch to IRS with a clothianidin-based formulation in 136 2019), which already experienced a large increase in monthly malaria cases by January 2020. 137 138 In sites that had not received IRS recently, average monthly cases from January 2020 through 139 December 2020 ranged from 518-1,068 and TPR from 47·5%-71·1%. These figures decreased to 140 251-716 and 32·5%-50·4%, respectively, from January 2021 through October 2021. Figure 3 141 shows plots of laboratory-confirmed malaria cases and the timing of the recent LLIN distribution 142 across the 10 non-IRS sites from January 2020 through October 2021. These figures indicate a 143 substantial increase in cases the first year of observation for some sites, but a general downward 144 trend in cases across the 10 sites over the 22 month study period for Objective 2. 145 146 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure 4 shows the mean number of cases across the 5 IRS sites and the 10 sites that have not 150 received IRS recently from January 2020 to October 2021 (corresponding to months 60 through 151 81 of IRS for the 5 sites where IRS was initiated and sustained). This figure shows an increase in 152 cases at IRS sites, particularly in the latter half of the observation window, while cases at non-153 IRS sites trended downward over the same time period. Figure 4 also shows the adjusted IRR 154 comparing cases at IRS sites to sites that have not received IRS recently. Coefficients and 95% 155 confidence intervals are also presented in Supplemental Table 2 . These findings indicate that 156 from January 2020 to November 2020, cases were significantly lower in IRS sites compared to 157 non-IRS sites. From December 2020 onward, the IRR crossed 1, indicating that cases at IRS sites 158 were higher than non-IRS sites, although we could not rule out a null or negative association in 159 these months. These results show that cases were 67% lower in IRS sites than non-IRS sites from 160 January 2020 through December 2020 (adjusted IRR = 0·33, 95% CI 0·17-0·63) and 38% higher 161 8 in tes m . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 21, 2022. ; https://doi.org/10.1101/2022.02.18.22271193 doi: medRxiv preprint from January through October 2021 (adjusted IRR = 1·38, 95% CI 0·90-2·11). Results were 162 consistent when including only laboratory-confirmed cases unadjusted for testing as the outcome 163 (Supplemental Figure 3) . 164 We did not observe corresponding increases in burden at 10 surveillance sites in neighboring 177 non-IRS districts that, unlike IRS districts, received "next generation" LLINs over the study 178 period. These findings suggest that in the setting of universal coverage with conventional 179 pyrethroid-only LLINs, the marked benefit of adding sustained IRS over the first five years had 180 9 e h 4. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. mixed results. A recent Cochrane review reported that adding IRS using a "pyrethroid-like" 195 insecticide to LLINs did not provide any benefits, while adding IRS with a "non-pyrethroid-like" 196 insecticide produced mixed results. 4 It is of note that none of the trials that evaluated the impact 197 of adding IRS with a "non-pyrethroid-like" insecticide assessed outcomes beyond two years. 198 More recently, observational studies evaluating the effectiveness of pirimiphos-methyl (Actellic 199 300CS®) in "real world" settings have documented impressive impacts of IRS in Mali 8,9 , 200 Ghana 10 , Zambia 11 , Kenya 12 , and Uganda. 7 This analysis contributes to observational data on the 201 impacts of sustained IRS beyond 6 years, in the context of the COVID-19 pandemic and a switch 202 to products containing the active ingredient clothianidin. 203 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. There are several potential factors that may be driving the increase in malaria burden in districts 205 receiving IRS. First, the timing of the increase corresponds to a shift in active ingredient from 206 pirimiphos-methyl to clothianidin-based formulations (primarily Fludora® Fusion, a 207 combination of clothianidin and deltamethrin). This change may have led to a partial loss of the 208 combined impact of the dual intervention (combining pirimiphos-methyl to pyrethroid LLINs), 209 which would be particularly detrimental as wide-spread pyrethroid resistance has been described 210 in Uganda. [13] [14] [15] Given that IRS districts received conventional pyrethroid LLINs in the 2020-211 2021 UCC campaign, pyrethroid resistance may also explain why burden increased at IRS sites 212 despite the campaign. Conversely, the 10 sites in neighboring districts where increases in burden 213 were not observed received "next generation" nets designed for areas with wide-spread 214 pyrethroid resistance. Of note, the one site (Dokolo) that received a single round of IRS with CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. ; https://doi.org/10.1101/2022.02.18.22271193 doi: medRxiv preprint A second potential contributor to the observed resurgence of malaria at sites receiving IRS is the 226 COVID-19 pandemic. An important concern has been the potential for delayed or inadequate 227 implementation of vector control measures due to the pandemic. 24, 25 In Uganda, the LLIN 228 distribution campaign was delayed by 5 months but successfully distributed over 28 million nets, 229 achieving over 90% coverage. Given that the delay in the UCC was country-wide, we do not 230 believe an increase in burden resulting from delayed net distribution would be observed strictly 231 in IRS sites as was the case in this study. The implementation of IRS campaigns did not appear 232 impacted by the COVID-19 pandemic; annual campaigns in 2020 and 2021 were not delayed and 233 coverage remained high (>90%, see Supplemental Table 3 ). We cannot rule out the potential for 234 This, however, would be unlikely to have occurred rapidly and simultaneously at all IRS sites at 247 a pace that would explain the resurgence observed in this study. In addition, this would not 248 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) while we attempt to control for seasonal effects and climate-related drivers of malaria burden 267 over time, it is certainly possible that more recent months over the observation period correspond 268 to an unusually high burden period in Uganda. However, overall secular trends are an unlikely 269 cause given the contemporaneous decline in malaria burden at nearby non-IRS sites. Third, the 270 outcome for this analysis is limited to case counts of laboratory-confirmed malaria captured at 271 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. of "next generation" LLINs due to evidence of pyrethroid resistance: one containing 305 deltamethrin and piperonyl butoxide (PBO; Permanet® 3·0) and one containing alpha-306 cypermethrin and pyriproxyfen (Royal Guard®). Among the surveillance sites included in this 307 study, the 5 sites in IRS districts were in sub-counties that received conventional pyrethroid nets 308 and the 10 sites in neighboring districts were in sub-counties that received "next generation" nets 309 (5 received Permanet® 3·0 nets and 5 received Royal Guard® nets). 310 311 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. ; https://doi.org/10.1101/2022.02.18.22271193 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. Objective 1 (to evaluate the impact of IRS on malaria burden in 5 districts over 6·75 of sustained 342 use), we utilized data from 5 MRCs from districts with where IRS was implemented in 2014. 343 These MRCs were selected because they had been active UMSP sites for at least 6 months prior 344 to the initiation of IRS. To compare changes in malaria burden from January 2020 through 345 October 2021 (years 6 & 7 following implementation of IRS) at sites receiving sustained IRS to 346 sites in neighboring districts that have not received IRS recently, we used data from 10 additional 347 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. ; MRCs. These sites were selected because they were in districts that neighbor the 5 IRS sites and 348 have been active UMSP sites since at least January 2020. Four of these sites were in 2 districts 349 that received IRS in the past; however, IRS was last implemented in 2017. The impact of these 350 previous IRS campaigns was no longer evident during the study period. For both objectives, the primary outcome was the monthly count of laboratory-confirmed 364 malaria cases at each MRC. To correct for monthly testing rates, we adjusted this count by 365 multiplying the number of individuals with suspected malaria but not tested each month by the 366 test positivity rate (TPR, the number who tested positive divided by the total number tested) in 367 that month. We then added the result to the number of laboratory-confirmed positive cases in that 368 month. As a sensitivity analysis, we re-specified the models including only laboratory-confirmed 369 case counts as the outcome. 370 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. ; We adjusted for time-varying variables that impact malaria burden and malaria case detection at 372 the health facility. This includes monthly precipitation 33 which was modeled non-linearly using 373 restricted cubic splines. Lags of 0, 1, 2, and 3 months were considered for precipitation; the 374 appropriate lag was selected by running univariable regressions with each lag and selecting that 375 which demonstrated the lowest Akaike's information criterion (AIC). We also included indicator 376 variables for month of the year (to adjust for season), the proportion of tests that were RDT 377 (vs. microscopy) in that month, and the number of individuals who attended the health facility 378 but were not suspected of having malaria in that month (to adjust for potential changes in care-379 seeking behaviors, particularly during the COVID-19 lockdown in Uganda). 380 381 For Objective 1, we specified mixed effects negative binomial regression models with random 383 intercepts for health facility. 7 Coefficients for the exposure variable were exponentiated to 384 represent the incidence rate ratio (IRR) comparing the incidence of malaria in the month of 385 interest relative to the baseline pre-IRS period. These models test the null hypothesis of no 386 difference of changes in IRS burden after the initiation of IRS compared to before the initiation 387 of IRS, adjusting for seasonal effects and time-varying changes in diagnostic testing and care 388 seeking. 389 390 For Objective 2, models were specified as mixed effects negative binomial regression models 391 with random intercepts for health facility. The binary indicator variable representing whether a 392 site was an IRS site or a non-IRS site was interacted with an indicator variable representing time 393 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. ; (an indicator representing month/year and, in a separate model, a categorical variable 394 representing January 2020-December 2020 and January 2021-October 2021). Coefficients for the 395 exposure variable combined with the interaction term were exponentiated to represent the 396 incidence rate ratio (IRR) comparing the burden of malaria IRS sites versus non-IRS sites over a 397 given period of time. These models test the null hypothesis of no difference between malaria 398 burden at IRS sites compared to non-IRS sites, adjusting for seasonal effects and time-varying 399 changes in diagnostic testing and care seeking. 400 401 The datasets generated during and/or analysed during the current study are available in GitHub at 403 the URL https://github.com/aeepstein/resurgence-irs-uganda 404 405 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 21, 2022. ; We would like to acknowledge the health workers at the health facilities that contributed data for 407 this study. We would like to thank the Ugandan Ministry of Health National Malaria Control 408 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 21, 2022. ; World malaria report 2020: 20 years of global progress and challenges The effect of malaria control on Plasmodium falciparum in Africa between 429 Systematic review of indoor residual spray efficacy and 431 effectiveness against Plasmodium falciparum in Africa Indoor residual spraying for preventing malaria in 434 communities using insecticide-treated nets Uganda National Malaria Control Division (NMCD) Resurgence of Malaria Following Discontinuation of Indoor Residual 440 Spraying of Insecticide in an Area of Uganda With Previously High-Transmission 441 The impact of stopping and starting indoor residual spraying on 443 Rapid reduction of malaria transmission following the introduction of 446 indoor residual spraying in previously unsprayed districts: an observational analysis of 447 Performance of IRS on malaria prevalence and incidence using 449 pirimiphos-methyl in the context of pyrethroid resistance in Koulikoro region An observational analysis of the impact of indoor residual spraying in 452 The Impact of 3 Years of Targeted Indoor Residual Spraying With 455 Pirimiphos-Methyl on Malaria Parasite Prevalence in a High-Transmission Area of 456 Northern Zambia Impact of indoor residual spraying with pirimiphos-methyl 300CS) on entomological indicators of transmission and malaria case burden in Migori 459 Pyrethroid Resistance Aggravation in Ugandan Malaria Vectors Is 461 Insecticide resistance status of the malaria mosquitoes: Anopheles 463 gambiae and Anopheles funestus in eastern and northern Uganda Months 1-36 of IRS 63 Months 1-36 of IRS 55 Months 1-36 of IRS 78,969 Baseline (11 months pre-IRS) 16 months pre-IRS) 15 Months 1-36 of IRS 62,161